← Back to Search

Financial Incentives + Text Messaging for Type 2 Diabetes

N/A
Waitlist Available
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Overweight or obese (BMI ≥85th percentile for age/sex, or ≥25 kg/m2 for participants ≥18 years)
Diagnosis with prediabetes or type 2 diabetes
Must not have
Severe cognitive impairment
Previously-diagnosed or current restrictive or purging eating disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to use financial incentives and text messaging to promote physical activity in obese adolescents and young adults with type 2 diabetes, who often have low levels of physical activity.

Who is the study for?
The BEAM trial is for overweight or obese adolescents and young adults aged 13 to 22 with prediabetes or type 2 diabetes. Participants must have a smartphone, agree to wear a Fitbit during the day, and not be very physically active already. Those with severe cognitive issues, eating disorders, disabilities affecting movement, who are pregnant, or don't speak English can't join.
What is being tested?
BEAM is testing an mHealth program that motivates physical activity using financial rewards and text messages in young people with type 2 diabetes or prediabetes. The interventions involve various combinations of reminders and incentives designed following behavioral economics principles.
What are the potential side effects?
Since this trial focuses on increasing physical activity through motivational texts and financial incentives rather than medication, side effects may include typical exercise-related discomforts such as muscle soreness but no drug-related side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am overweight or obese according to BMI standards for my age and sex.
Select...
I have been diagnosed with prediabetes or type 2 diabetes.
Select...
I am between 13 and 22 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe problems with my memory or thinking.
Select...
I have been diagnosed with an eating disorder that involves restricting or purging.
Select...
I have a disability that affects my ability to walk or be physically active.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Moderate to Vigorous Physical Activity (MVPA)
Secondary study objectives
Daily Step Count

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

16Treatment groups
Experimental Treatment
Group I: Condition 9Experimental Treatment1 Intervention
1FLD=One text per day, fixed goal, loss incentive, daily goal time period.
Group II: Condition 8Experimental Treatment1 Intervention
2RGW=Two texts per day, ramped goal, gain incentive, weekly goal time period.
Group III: Condition 7Experimental Treatment1 Intervention
2RGD=Two texts per day, ramped goal, gain incentive, daily goal time period.
Group IV: Condition 6Experimental Treatment1 Intervention
2RLW=Two texts per day, ramped goal, loss incentive, weekly goal time period.
Group V: Condition 5Experimental Treatment1 Intervention
2RLD=Two texts per day, ramped goal, loss incentive, daily goal time period.
Group VI: Condition 4Experimental Treatment1 Intervention
1RGW=One text per day, ramped goal, gain incentive, weekly goal time period.
Group VII: Condition 3Experimental Treatment1 Intervention
1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
Group VIII: Condition 2Experimental Treatment1 Intervention
1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
Group IX: Condition 16Experimental Treatment1 Intervention
2FGW=Two texts per day, fixed goal, gain incentive, weekly goal time period.
Group X: Condition 15Experimental Treatment1 Intervention
2FGD=Two texts per day, fixed goal, gain incentive, daily goal time period.
Group XI: Condition 14Experimental Treatment1 Intervention
2FLW=Two texts per day, fixed goal, loss incentive, weekly goal time period.
Group XII: Condition 13Experimental Treatment1 Intervention
2FLD=Two texts per day, fixed goal, loss incentive, daily goal time period.
Group XIII: Condition 12Experimental Treatment1 Intervention
1FGW=One text per day, fixed goal, gain incentive, weekly goal time period.
Group XIV: Condition 11Experimental Treatment1 Intervention
1FGD=One text per day, fixed goal, gain incentive, daily goal time period.
Group XV: Condition 10Experimental Treatment1 Intervention
1FLW=One text per day, fixed goal, loss incentive, weekly goal time period.
Group XVI: Condition 1Experimental Treatment1 Intervention
1RLD=One text per day, ramped goal, loss incentive, daily goal time period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
1FLD
2021
N/A
~80
2RGD
2021
N/A
~80
1RLD
2021
N/A
~80
1RGD
2021
N/A
~80
2RLW
2021
N/A
~80
1FLW
2021
N/A
~80
1FGD
2021
N/A
~80
2FLD
2021
N/A
~80
2FGD
2021
N/A
~80
2RLD
2021
N/A
~80
2RGW
2021
N/A
~80
1FGW
2021
N/A
~80
2FLW
2021
N/A
~80
2FGW
2021
N/A
~80
1RGW
2021
N/A
~80
1RLW
2021
N/A
~80

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,784 Previous Clinical Trials
16,357,216 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,439 Previous Clinical Trials
4,324,749 Total Patients Enrolled

Media Library

2FGD Clinical Trial Eligibility Overview. Trial Name: NCT04874415 — N/A
Type 2 Diabetes Research Study Groups: Condition 1, Condition 8, Condition 13, Condition 14, Condition 6, Condition 2, Condition 3, Condition 5, Condition 15, Condition 4, Condition 9, Condition 7, Condition 16, Condition 12, Condition 10, Condition 11
Type 2 Diabetes Clinical Trial 2023: 2FGD Highlights & Side Effects. Trial Name: NCT04874415 — N/A
2FGD 2023 Treatment Timeline for Medical Study. Trial Name: NCT04874415 — N/A
~19 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top